Overall survival results of AGO-OVAR16: a phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer
Nom du journal : Gynecol Oncol
Année : 2019
Volume : 155
Page de départ : 186
Page de fin : 191